<<<Next point of any major interest would be an interim look at pivotal trial data. That will be a over a year.>>>
Trial to watch is renal cell, 800 patient pivotal, data should be out in just a few months.
Press Release Source: Antigenics Inc.
Antigenics Appoints Jill M. Forrest as Vice President of Marketing and Sales
Thursday October 13, 7:00 am ET
NEW YORK--(BUSINESS WIRE)--Oct. 13, 2005--Antigenics Inc. (NASDAQ: AGEN - News) today announced that Jill M. Forrest has been appointed to the newly created position of vice president of marketing and sales. In this role, Ms. Forrest will be responsible for leading all precommercial and commercialization activities in preparation for the launch of Oncophage® (vitespen; formerly HSPPC-96) and other late-stage product candidates.
"With encouraging data from our Phase 3 melanoma trial of Oncophage and our plans to build a commercial cancer presence expeditiously, it's an appropriate time for us to bring in a professional of exceptional attributes," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "Jill's experience in launching first-to-market oncology compounds as well as her extensive marketing and sales background in a broad range of oncology treatment settings will be invaluable to us as we prepare to build a commercial presence in oncology."
Ms. Forrest brings to Antigenics 20 years of oncology expertise, including experience in clinical trials, sales, sales training and management, marketing and global product development. She was most recently director of global marketing at Bristol-Myers Squibb Oncology, where she was responsible for the premarketing and launch efforts for the novel oncology compound vinflunine. As a senior region business director, she played a key role in the launch of Erbitux(TM) (cetuximab), a targeted biological therapy for colorectal cancer, and led national sales performance for three consecutive years. As a director of marketing, she led the launch of the chemotherapy TAXOL® (paclitaxel) as an adjuvant treatment in breast cancer, as well as drove marketing efforts, resulting in a 40 percent increase in breast cancer sales. Ms. Forrest received a BA in psychology from the University of Kansas.
About Antigenics |
